So in this one, Segun gives us a nice, concise approach to cardiogenic shock and reminds us of the key clinical priorities!
For those who want more, see here for The Essentials On-Demand!
We’re really excited for the third edition of H&R!
Last year was great, all thanks going to our awesome faculty, and this year, we’re planning on taking it yet to another level. We’ve added some new faculty members who’ll be bringing some interesting perspectives, and there will be a pervasive theme across the two days to really get everyone’s understanding and management of the oft-overlooked venous/right side of things. This is a clear evolution in clinical practice that, paired with POCUS, is really a game changer across a wide range of pathologies. Expect to leave from these two days with at least one extra notch on your belt.
So, some slight structural adjustments. The Hospitalist angle gets a pre-conference course, focusing on very practical, applied and critically important topics for the ward patients, including a POCUS workshop to get some hands-on work. Felipe Teran and his team will bring back Resuscitative TEE, and we will add a Resuscitationists’ Toolbox pre-conference in which to learn or practice certain key skills. The two main conference days will be packed full of interesting talks, both by traditional but exceptional academics, as well as many of the top notch #FOAMed educators. The tail end will have some awesome workshops, and, on a first-come, first-served basis, you will be able to book some one-on-one time with faculty for hands-on or discussion. More on this soon.
May 20th – PreConference courses (Resus TEE, Resuscitationist Toolbox, Hospitalist Course, Combat for MDs)
May 21st – H&R Day 1
May 22nd – H&R Day 2
All of this will be in Montreal, Quebec, Canada, most probably Santa Cabrini Hospital, but full details to follow!
early bird registration starts October 15th until November 15th.
Follow the blog and bookmark this page, will add links to more in the next weeks.
Also, if anyone has any topic or workshop requests, please leave them in the comments and they will be seriously considered!
The lineup so far… DUGGAN, DENAULT, FARKAS, SPIEGEL, NEMETH, TERAN, HAYCOCK, WEIMERSHEIMER, AJJAMADA, OLUSANYA, KENNY, MAGDER, MEYERS, BEAUBIEN-SOULIGNY, GUEZ, CHEN, GARRONE… and more to come!
So I recorded a chat with Domagoj (@domagojsono in the twitterverse), an anaasthetist-resuscitationist-intensivist from Freiburg a few months ago, but with H&R2019 and its aftermath, been slow in processing a lot of stuff I’ve got stocked… Apologies!
So in this one, DOmagoj and I discuss a bunch of resus topics, from eCPR to tissue oximetry. I’m really jealous of the fact that he does prehospital work with an ECMO van!!! …and with cool gear and of course, POCUS!
Here is the chat, hope it leads to thoughts, discussion and contribution!
And here are some links:
So these two had some follow up discussion in regards to this prior post, which is definitely worth a read. My editorial comments in bold.
Jon-Emile, thanks for your follow up and taking the time to look at the studies I referenced. I hadn’t seen your reply until Phil posted this. I gather your concerns primarily rest on the assumption that mPAP would rise higher (due to reaching the limits of the compliance of the pulmonary vasculature) than the rise in LAP, causing an increase in the delta mPAP-LAP and thus making the TRpg/RVOT VTI methods invalid as a way to know what the PVR is, as well as the concept of a calculated PVR in cases of significantly elevated LAP.
I absolutely believe you are right in postulating that this does indeed occur, but I think that the fact that the LAP required to be significantly increased to cause this phenomenon would tend to “blunt” the delta between the mPAP and LAP as well, therefore also simultaneously helping to decrease the pressure/flow ratio that we are taking about to calculate PVR. In other words, the LAP required to cause what you are talking about also serves to pull back the error in PVR calculation a bit too. I’m sure there is a complex interplay between pulmonary vascular compliance and LAP that would make prediction of all this difficult in real life, but again I do agree with you that this is real and perhaps, common.
Having said that, I still think that the PVR estimation by the TR/VTI method works as there were enough patients with elevated LAPs included in the studies I showed you and the findings were replicated. After listening to your concerns, I will probably wonder a bit now about how close the predicted PVR is to the actual PVR when I see elevated LAP as well though!
Which brings me to my next point. I don’t think I would be fooled by a calculated PVR error scenario because I’m going to have a good idea about if there is elevated LAP or not due to the fact that I’m also seeing the left side of the heart dynamics on POCUS. Furthermore, I can get a relatively good idea about how high a LAP is by applying some Doppler techniques as well. Where this can get a bit murky is when I suspect elevated PVR and also see elevated LAPs on POCUS at the same time.
In an offline email exchange between you, I, and a group of people I thought would be interested, I presented one of these cases where I believed there to be both increased PVR and LAP. So the question at hand was what was causing the patient’s hemodynamic compromise. In the email, I purposely included information about the pulmonary valve regurgitant jet as it was very apropos to your points and the concerns you had described. The answer to the question of whether the PVR elevation was artifactual (due to what you have described) or real, was settled in both our minds by the fact that in the pulmonary valve regurgitant jet Doppler pattern, there was clear evidence that there was quite a gap between the LAP and the dPAP, thus pretty much proving a pre-capillary elevated PVR mechanism was in play as well as the elevation in LAP to the cause of the pulmonary HTN.
So I’d like to reinforce what you have pointed out, as it really is a key point: If you need to know if the PVR is real or not, the delta of the dPAP to LAP is really the only way to know for sure. However, I think I can still trust my assessment by looking at the echo as a whole and putting everything together in the occasional cases where a PR jet isn’t available to see as well.
Again, thanks so much Jon for pointing out where things may go sideways with your superior and deep understanding of physiology. You are really great to discuss these things with!
Thanks for turning this into a dedicated post Phil.
I rambled my way around saying that my concern is the gold standard, not echo! If i were Rory, I would have called my post “The Case of The Flawed Gold Standard” (he may already have used this title).
The flawed gold standard is the calculated pulmonary vascular resistance from a right heart cath (note that in the pulmonary hypertension literature, that the PA Catheter-based definition does not include PVR!). One reason that PVR is not used is because of its many physiological/mathematical problems – probably first made explicit in the mid 1980s
Versprille A. Pulmonary vascular resistance. A meaningless variable. Intensive Care Med. 1984;10(2):51-3. PMID: 6715677
Korbin, I have no doubt that when you perform bedside TTE, that you have a very keen ability to discern left-sided PVR elevations from “true” pulmonary vascular PVR elevations – but not everyone is you! It actually doesn’t take very high left atrial pressures to cause the calculated PVR to rise and what i find most troubling is the nomenclature – because of the therapeutic implications. Calling it elevated “pulmonary vascular resistance” implies that **pulmonary vascular** resistance is high (even though it may not be) – so there may be the desire to give pulmonary vasodilators … which can make things worse! (see the SIOVAC trial).
That’s my clinical question exactly. Should I give pulmonary vasodilators or no?
What I’d really be interested to see … would be to measure the TRpg/RVOT VTI in patient with true hypertensive emergency (ideally without hypoxemia or significant pulmonary problems) – before, during and after treatment. I suspect that a very high LV afterload on presentation could cause the TRpg/RVOT VTI to be elevated (and if you put a right heart cath into the patient, the calculated PVR would also be high), even though the problem is, arguably, entirely in the systemic circulation. In theory, treatment with systemic vasodilators would lower impedance of the systemic circulation (the LV afterload) without any true ‘pulmonary vasodilation” — yet, I suspect that the TRpg/RVOT VTI would fall with therapy.
I know Korbin is now on the hunt for this exact patient. Looking forward to Part 3 of this discussion when he does find him or her!
So here was a late-breaker talk at H&R2019. Portal vein pulsatility and hyponatremia by a nephrologist – intensivist. Love it. Sharad, a really great guy, also recently published a case report on this topic.
There is a lot of stuff on venous congestion in the woodwork, some of which we are involved in, but also some springing up from different places, and this is really exciting, because POCUS gives you a non-invasive tool to assess and differentiate pathological degrees of congestion that really nothing else can with as much breadth, and as part of a comprehensive exam.
Venous POCUS is worth learning, and keep your eye on this space for how it evolves as a clinical tool. Our VEXUS classification will soon have some real substance behind it.
For those who want more H&R2019, the Essentials can be found here!
And here’s Sharad!
So I’m still trying to digest the RVOT Doppler physiology and working my hand at generating the best views and Doppler angles I can (See previous post on RVOT Doppler here). Not sure yet how this will fit in to my clinical practice but I think it’s worth shining a light into this murky pseudo-science of resuscitation. These guys are helping define its potential use… Naturally, this is bleeding-edge stuff. Use it to try to understand what’s going on with your patient’s physiology, don’t use this on board exams! My comments in bold.
Now for the big guns…
Jon-Emile Kenny (@heart_lung), pulmccm.org, heart_lung.org
Hey Guys – great discussion as always!
One thing that I find confusing on this topic, and is helpful – i think – when scrutinizing the literature, is the difference between ‘impedance’ and ‘resistance.’ Elevated vascular ‘resistance’ is often used too broadly; for example, true/pure WHO II pulmonary venous hypertension [say from acute left atrial pressure hypertension, but before chronic, compensatory pulmonary arterial changes] is actually typified by a *decrease* in resistance, but an increase in *impedance.* To make things more confusing, acute left atrial hypertension will often display a high “resistance” mathematically … even though, the true resistance can be low. What am i saying? if you imagine an acute increase in the left atrial pressure, the pulmonary venous beds and pulmonary vascular beds “recruit and dilate” backwards [why we see cephalization on the CXR] typically from the bottom to the top of the lungs up the hydrostatic gradient. Recruitment and dilation actually *increases* the cross-sectional radius/area of the vascular beds — a true decrease in resistance [Poiseuille what?]! But, as these vascular beds are engorged, they reach that infamous, hockey-stick-shaped compliance curve point [go leafs go!], where the vessels become really stiff … that is, the compliance falls such that each ejection the RV throws into this dilated circulation, the pressure rises dramatically [especially the systolic pulmonary pressure] …
This I think is a key concept to understand and keep in mind when analyzing the venous system. The physical characteristics are more akin to a floppy plastic bag or balloon, with little rise in pressure until a certain point, then a sharp one – Jon’s “hockey stick.” It was Jon who made me realize that, with exposure to chronically elevated right atrial pressures, one could have a very big IVC (say 25-30mm, but in fact a low CVP, whereas in normal IVCs exposed to normal CVPs, that sharp rise in pressure probably occurs somewhere around 20mm. Hence, the + value we use in the PAP calculation using TR Vmax for the RAP may be very inaccurate in chronically elevated PAP… Food for thought.
Thus, the calculated pressure gradient rises and and the calculated resistance falls, but what has actually happened is that compliance has fallen, not “resistance”. More broadly, the term “impedance” is composed of compliance, resistance and something called the characteristic impedance [the Windkessels!]. Typically what abnormal RV Doppler shows you is that *impedance* has risen. At the end, you are often still left with the why? Impedance can rise when “true resistance “falls, but compliance also falls [as above] – yet the calculated RVSP/regurgitant jet will also rise. The linked papers are fantastic, but they both excluded patients with left heart disease, so you can be more confident that the RVOT abnormalities seen are related to true ‘pre-capillary’ problems. I’d be willing to bet [and if there’s data, i’d be interested to read it] that patients with pure WHO II pulmonary venous hypertension have very similar abnormalities on the right side. The key means to distinguish – as Korbin talks about – is really looking at the left heart [E/e’] and clinical context to get a better sense of what’s going on.
What would also be interesting would be to look at acutely “decompensated” true left heart disease in volume overload and correlated with RVOT morphology and great vein Doppler velocimetry. My guess is that as you decongest the pulmonary veins [increase their compliance] that the RVOT envelope “pulsatility” goes away [the RV ejection envelope appears more rounded] as does the venous pulsatility in the great veins and intra-renal veins! It’s all about energy transfer … moving away from excessive potential energy trapped in distensible structures [i.e. congestion] to kinetic energy [normal, forward blood flow]
Thanks for the reply Jon-Emile, as usual you bring an incredible amount of intelligent well thought out points.
As you mentioned, afterload is much better described in terms of the 3-element Windkessel model as resistance is only one component of said model (the other factors being vascular compliance and characteristic impedance). Please correct me if I’m wrong, but I believe that the most practical and easiest way to non-invasively determine arterial load is to calculate the Ea (formula: (SBP*0.9)/SV). This would include all of the factors that determine afterloading conditions instead of simply using resistance as it is only one of those factors.
Clinically speaking, I think it is important to address why afterloading conditions are abnormal when we come across undifferentiated pulmonary HTN in the acute setting. Practically in my mind, this is simply finding if the pHTN is due to post-capillary “back pressure” from elevated left atrial pressures or due to elevated pre-capillary pulmonary vascular resistance (or could be some combination of both of course). Both of these conditions can cause elevated pulmonary artery pressures, as you have pointed out, and there are a few other contributors to the afterload as well that we are ignoring (or else we’d blissfully nerd out all day and forget to take care of the patients).
I agree with this concept. This is what may direct me to use pulmonary vasodilators, whether inhaled or even the choice of milrinone or vasopressin (not a vasodilator per se but a non-pulmonary vasoconstrictor). If all the pulmonary hypertension is post-capillary, there would be little or no benefit. This important decision point is what prompts me to look into this whole right-sided Doppler thing… Let’s see what else Korbin has to add!
So how can find out the cause(s) of the elevated PAP? Is it resistance or back pressure from the left atrium? This is essentially the topic of the post. Because PVR=(mPAP-LAP)/CO, it has been suggested that the TR gradient can be a surrogate for the mPAP-LAP and RVOT VTI be a surrogate for CO. Thus if the ratio is high, we can assume that a significant component of the pHTN is due to resistance in addition to or to the exclusion of the contribution of LAP. You have rightly questioned and very well explained why you wonder if these are valid assumptions that translate to the finding the clinical causes of pHTN.
You pointed out that the cited papers in the post excluded patients with LV failure, thus bringing into question if the TR/VTI ratio methods and their permutations are actually detecting PVR as the primary etiology of the pHTN or are corrupted by elevations in LAP. Here are 3 papers that included a significant number of patients with pHTN and elevated PCWPs as measured by RHC that show that the TR/VTI methods do seem to work to detect PVR elevations themselves even if the LAP are high:
1) Am J Cardiol. 2013 September 15; 112(6): 873–882. doi:10.1016/j.amjcard.2013.05.016.
2) J Am Soc Echocardiogr 2013;26:1170-7.
3) J Am Coll Cardiol 2003;41:1021–7.
Somewhere in my files I have a study that shows that the mid systolic notch is fairly specific for high PVR and independent of LAP as well. but apologies, I’d have to look for it.
As I might have mentioned in the audio portion of the post (I can’t remember), there is a second method to flesh out PVR from LAP causes of pHTN. First, you need to find a good estimation of the LAP. ECHO has multiple ways of various accuracies to get a number. The formulas are listed above. I don’t believe any of them are validated in acutely sick patients though. Once you have a LAP number, turn your attention to the pulmonary valve regurgitant jet which will almost always be there if there’s pHTN. The wave form is sort of down-sloping trapezoidal lasting through diastole. The velocity at end-diastole can be squared, multiplied by 4, then added to the RAP to give you the end-diastolic PAP. This is normally < 6 mmHg higher than the LAP pressure measurement, if it is a bit more higher, there likely is increased PVR. This is the same principle used in a RHC, where the inflation of the balloon stops flow and therefore eliminates resistance so that the PCWP can be measured and differentiated from the dPAP. The problem with this method is that it doesn’t work as well as the TR/VTI methods
I really enjoyed your thoughts about how Doppler waveform patterns may be affected once compliance limits have been reached, and I’m sure there is something to this that is real as well no doubt! I thought it might be helpful to provide you with the additional studies that included the patients with high LAP, and do a bit of re-explaining/restating your points to anyone new to this stuff.
Thanks again Jon!
Hey Korbin – thanks for the references – I’ll dig into them. My main concern is that the mPAP-LAP will disproportionately rise (mostly because the sPAP disproportionately rises) when the left atrial pressure is high … that is when it’s actually not a “resistance” problem but rather a back pressure problem, the mathematical resistance is high. As you mention, this is why there’s a push to move away from “PVR” with RHC and more towards the dPAP-PCWP gradient which should be less than 6 mmHg. I made a cartoon describing this in an old post (https://pulmccm.org/critical-care-review/icu-physiology-1000-words-folly-pulmonary-vascular-resistance/). Thanks for these references, I’ll read them and see if they make sense from the framework I’ve adopted – which is entirely stolen from this great article
Naeije, R., et al., The transpulmonary pressure gradient for the diagnosis of pulmonary vascular disease. Eur Respir J, 2013. 41(1): p. 217-23.
Maybe Phil should do a point-counterpoint podcast where Rory comes in at the end and shakes his head because nothing really matters in the end.
Thanks Jon, I would like to see what you think. Thanks back at you for the reference you mentioned in your reply. And you’re hilarious!
I had a read of the references that you provided, thank you. I think my concerns still apply, however. My main concern is what is being used as the gold standard for ‘pulmonary vascular resistance.’ An elevated calculated pulmonary vascular resistance (e.g. in WU) doesn’t actually tell you where the pathology is. the assumption is that an elevated calculated pulmonary vascular resistance is caused by a high pre-capillary resistance in the pulmonary circulation, but this isn’t necessarily true. as i showed in that post that i linked to (https://pulmccm.org/critical-care-review/icu-physiology-1000-words-folly-pulmonary-vascular-resistance/) … if one were to acutely cross-clamp the descending aorta, below the diaphragm, the calculated pulmonary vascular resistance would rise, even though the pathology is totally outside of the thorax!! i have no doubt that the TRV / RVOT-VTI would also rise in that very same patient with the cross-clamped descending aorta such that the good correlation between the calculated ‘pulmonary vascular resistance’ and the TRV / RVOT-VTI is maintained – but the pathology is in the abdomen – not the pulmonary vascular tree! So many exclamation marks; but i’m not yelling. In a hypothetical patient with a cross-clamped descending aorta, one might be tricked into giving a pulmonary vasodilator — but that would be the absolute wrong thing to do, even though the calculated pulmonary vascular resistance is high. The treatment is to afterload reduce the struggling LV (remove the cross clamp) — which would then lower the calculated “pulmonary” vascular resistance and the TRV / RVOT-VTI.
the problem in reasoning lies in what happens with the left atrial pressure rises (as would happen if one acutely cross-clamped the descending aorta). it is assumed that as the LAP rises that the mPAP – LAP gradient stays the same or rises in proportion. but what happens when the LAP rises is that the mPAP rises disproportionately because of pulmonary vascular engorgement/stiffening (in fact, the pulmonary vascular resistance has fallen because of recruitment and dilation of the pulmonary tree). what *does* rise in proportion is the dPAP – LAP gradient [should stay below 7 mmHg]. i strongly suspect that the ability of the TTE to detect/calculate the dPAP – LAP gradient is not yet refined enough because there is a lot of supposition and inference when making dPAP and LAP measurements with pulsed wave Doppler.
alas, with either an elevated TRV / RVOT-VTI (or calculated pulmonary vascular resistance from a RHC), one still doesn’t know if it’s purely a left-sided problem (e.g. purely elevated LV afterload) – which could seriously alter management. to know that, i think that a full interrogation of the left heart and pulmonary veins must be done before knowing exactly what an elevated TRV / RVOT-VTI specifically identifies. in addition to that vascular resistance post above, i dug into some more of this in a discussion on the SIOVAC trial a while back (https://pulmccm.org/randomized-controlled-trials/choose-wisely-avoid-sildenafil-pulmonary-hypertension-corrected-left-heart-valvular-disease-siovac-trial/) – which, in my opinion, should never have passed ethics.
So this is really fascinating stuff. I must admit both Korbin and Jon make excellent points, and for now am not sure if and how to use RV Doppler in clinical decision-making, but until then will be sure to polish up these skills so that they are ready for prime time, and use them in observation of physiology in my shock patients. We’ll see what conclusions I draw.
So here is a really solid lecture by Rory (@EMnerd) on his approach to acid base disorders. Definitely worth a listen, and probably the way I will go about teaching it from now on!
His slides can be found here.
For those who want more H&R2019, click here. Category 1 CME likely to come in the next weeks!
the best is yet to come.
This WordPress.com site is the bee's knees
where everything is up for debate . . .
Brazilian Jiu Jitsu for Wrestlers
Spheres of basic emergency medicine knowledge
Critical discussions on critical care
a blog for thinking docs: blending good evidence, physiology, common sense, and applying it at the bedside!